Empery Asset Management LP Makes New Investment in Tenaya Therapeutics, Inc. $TNYA

Empery Asset Management LP bought a new position in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) during the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 5,414,101 shares of the company’s stock, valued at approximately $3,852,000. Tenaya Therapeutics accounts for about 3.4% of Empery Asset Management LP’s holdings, making the stock its 7th largest position.

Other institutional investors have also modified their holdings of the company. GSA Capital Partners LLP raised its holdings in shares of Tenaya Therapeutics by 220.2% during the 4th quarter. GSA Capital Partners LLP now owns 1,478,612 shares of the company’s stock worth $1,052,000 after acquiring an additional 1,016,808 shares during the period. Schonfeld Strategic Advisors LLC purchased a new position in shares of Tenaya Therapeutics during the 3rd quarter worth $755,000. Jefferies Financial Group Inc. purchased a new position in shares of Tenaya Therapeutics during the 3rd quarter worth $99,000. Jane Street Group LLC raised its holdings in shares of Tenaya Therapeutics by 1,958.7% during the 2nd quarter. Jane Street Group LLC now owns 376,068 shares of the company’s stock worth $230,000 after acquiring an additional 357,801 shares during the period. Finally, Cerity Partners LLC raised its holdings in shares of Tenaya Therapeutics by 403.5% during the 2nd quarter. Cerity Partners LLC now owns 110,336 shares of the company’s stock worth $67,000 after acquiring an additional 88,424 shares during the period. Hedge funds and other institutional investors own 90.54% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. William Blair reiterated an “outperform” rating on shares of Tenaya Therapeutics in a report on Thursday, March 12th. Leerink Partners reiterated an “outperform” rating and set a $2.00 price target on shares of Tenaya Therapeutics in a report on Thursday, March 12th. Lifesci Capital upgraded Tenaya Therapeutics to a “strong-buy” rating in a report on Thursday, March 5th. Chardan Capital reiterated a “buy” rating and set a $8.00 price target on shares of Tenaya Therapeutics in a report on Thursday, March 12th. Finally, Wall Street Zen lowered Tenaya Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 6th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Tenaya Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $4.00.

Tenaya Therapeutics Trading Down 1.4%

Shares of TNYA opened at $0.70 on Thursday. The firm has a market cap of $151.90 million, a P/E ratio of -1.49 and a beta of 2.82. Tenaya Therapeutics, Inc. has a 12-month low of $0.53 and a 12-month high of $2.35. The company’s 50-day moving average price is $0.77 and its 200 day moving average price is $0.81.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.09). The company had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $7.50 million. Equities research analysts forecast that Tenaya Therapeutics, Inc. will post -0.42 earnings per share for the current year.

Tenaya Therapeutics Profile

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.